Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized …
M Goldberg, YP Li, JF Johanson… - Alimentary …, 2010 - Wiley Online Library
M Goldberg, YP Li, JF Johanson, AW Mangel, M Kitt, DT Beattie, K Kersey, O Daniels
Alimentary pharmacology & therapeutics, 2010•Wiley Online LibraryAliment Pharmacol Ther 2010; 32: 1102–1112 Summary Background Velusetrag is an orally
active 5‐HT4 receptor agonist of potential benefit in treating chronic idiopathic constipation.
Aim To evaluate the efficacy, safety and tolerability of velusetrag in chronic idiopathic
constipation. Methods After a 2‐week baseline period, patients [< 3 spontaneous bowel
movements (SBM)/week] received placebo or velusetrag (15, 30 or 50 mg) daily for 4 weeks
in a randomized, double‐blind design, followed by a 1‐week follow‐up period. The primary …
active 5‐HT4 receptor agonist of potential benefit in treating chronic idiopathic constipation.
Aim To evaluate the efficacy, safety and tolerability of velusetrag in chronic idiopathic
constipation. Methods After a 2‐week baseline period, patients [< 3 spontaneous bowel
movements (SBM)/week] received placebo or velusetrag (15, 30 or 50 mg) daily for 4 weeks
in a randomized, double‐blind design, followed by a 1‐week follow‐up period. The primary …
Aliment Pharmacol Ther 2010; 32: 1102–1112
Summary
Background Velusetrag is an orally active 5‐HT4 receptor agonist of potential benefit in treating chronic idiopathic constipation.
Aim To evaluate the efficacy, safety and tolerability of velusetrag in chronic idiopathic constipation.
Methods After a 2‐week baseline period, patients [<3 spontaneous bowel movements (SBM)/week] received placebo or velusetrag (15, 30 or 50 mg) daily for 4 weeks in a randomized, double‐blind design, followed by a 1‐week follow‐up period. The primary endpoint was the change from baseline in weekly SBM frequency averaged over the 4‐week treatment period.
Results Patients receiving velusetrag (15, 30 and 50 mg) achieved statistically and clinically significant increases in weekly SBM frequency relative to those receiving placebo. Mean increases were 3.6, 3.3 and 3.5 SBM/week respectively, compared with 1.4 SBM/week for placebo (P < 0.0001). Statistically significant increases in the weekly frequency of complete SBM (CSBM) were also reported (mean increases of 2.3, 1.8 and 2.3 for 15, 30 and 50 mg velusetrag respectively, compared with 0.6 for placebo). Common adverse events associated with velusetrag were diarrhoea, headache, nausea and vomiting, generally occurring during the initial days of dosing.
Conclusion Velusetrag was efficacious and well tolerated in patients with chronic idiopathic constipation (ClinicalTrials.gov identifier NCT00391820).
Wiley Online Library